Seneca House Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-6,157
Closed -$226K 82
2023
Q2
$226K Sell
6,157
-2,007
-25% -$78.1K 0.11% 77
2023
Q1
$333K Sell
8,164
-1,003
-11% -$43.3K 0.17% 67
2022
Q4
$470K Sell
9,167
-1,338
-13% -$64.1K 0.26% 59
2022
Q3
$460K Sell
10,505
-112
-1% -$5.44K 0.34% 56
2022
Q2
$557K Sell
10,617
-3,069
-22% -$156K 0.36% 56
2022
Q1
$709K Sell
13,686
-953
-7% -$49.4K 0.37% 53
2021
Q4
$864K Buy
14,639
+3,046
+26% +$151K 0.46% 46
2021
Q3
$499K Sell
11,593
-440
-4% -$19.5K 0.3% 58
2021
Q2
$471K Buy
12,033
+1,227
+11% +$47.7K 0.31% 48
2021
Q1
$391K Sell
10,806
-18
-0.2% -$639 0.28% 53
2020
Q4
$398K Sell
10,824
-103
-0.9% -$3.78K 0.29% 51
2020
Q3
$380K Buy
10,927
+545
+5% +$19.1K 0.3% 49
2020
Q2
$322K Buy
10,382
+3,192
+44% +$108K 0.27% 55
2020
Q1
$223K Buy
7,190
+250
+4% +$8.52K 0.24% 58
2019
Q4
$258K Sell
6,940
-200
-3% -$7.12K 0.22% 77
2019
Q3
$243K Sell
7,140
-1,138
-14% -$41.4K 0.23% 76
2019
Q2
$342K Buy
8,278
+961
+13% +$38.2K 0.31% 72
2019
Q1
$295K Buy
7,317
+1,142
+18% +$45.7K 0.26% 81
2018
Q4
$256K Buy
6,175
+751
+14% +$31.2K 0.24% 80
2018
Q3
$227K Buy
+5,424
New +$209K 0.18% 91

Other funds holding PFE

Seneca House Advisors's PFE Position: Q3 2023 in Review

Seneca House Advisors sold out of Pfizer (PFE) in Q3 2023, closing a stake of 6,157 shares — an estimated $226K sold.

Seneca House Advisors first reported a position in PFE in Q3 2018 and held it in 20 quarters. The position peaked at $864K in Q4 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Seneca House Advisors reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Seneca House Advisors sold 6,157 Pfizer shares in Q3 2023, an estimated $226K.
  • Seneca House Advisors first reported a position in Pfizer in Q3 2018 and held it in 20 quarters.
  • Seneca House Advisors's Pfizer position peaked at $864K in Q4 2021.
  • 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Seneca House Advisors's 13F filing for Q3 2023, filed 13 Oct 2023.